Get the Stockscreener App
0.6615
8.75%
-0.0634
Pharmacyte Biotech Inc stock is traded at $0.6615, with a volume of 197.82K.
It is down -8.75% in the last 24 hours and down -26.34% over the past month.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
See More
Previous Close:
$0.7249
Open:
$0.74
24h Volume:
197.82K
Relative Volume:
0.06
Market Cap:
$6.70M
Revenue:
-
Net Income/Loss:
$-1.13M
P/E Ratio:
-1.4409
EPS:
-0.4591
Net Cash Flow:
$-4.60M
1W Performance:
-5.50%
1M Performance:
-26.34%
6M Performance:
-21.25%
1Y Performance:
-58.91%
1-Day Range:
$0.6506
$0.7436
1-Week Range:
$0.6506
$0.81
52-Week Range:
$0.63
$1.90
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
Name
Pharmacyte Biotech Inc
Sector
Industry
Phone
(917) 595.2850
Address
3960 HOWARD HUGHES PARKWAY, LAS VEGAS
Compare PMCB vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 2.24 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.22 | 3.25B | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
8.69 | 536.01M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.32 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
2.8999 | 277.51M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DWLD
Davis Select Worldwide ETF
|
46.01 | 0 | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc Stock (PMCB) Latest News
PharmaCyte Biotech (OTCMKTS:PMCBD) Trading 5.9% Higher – Time to Buy? - Defense World
Volume Summary: What is SIM Acquisition Corp Is P E ratio telling usJuly 2025 Catalysts & Trade Opportunity Analysis Reports - baoquankhu1.vn
Dow Update: Is PharmaCyte Biotech Inc vulnerable to short sellersMarket Risk Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
PharmaCyte Biotech Inc. (PMCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is PharmaCyte Biotech Inc. trading at a discountWeekly Stock Report & Weekly High Momentum Picks - mfd.ru
Is PharmaCyte Biotech Inc. vulnerable to short sellersJuly 2025 Price Swings & Fast Momentum Stock Entry Tips - bollywoodhelpline.com
Dividend Watch: Is PharmaCyte Biotech Inc in a bullish channelJuly 2025 Short Interest & AI Driven Price Predictions - baoquankhu1.vn
PharmaCyte Biotech (OTCMKTS:PMCBD) Shares Down 4.3% – Time to Sell? - Defense World
Bull Run: Why PharmaCyte Biotech Inc stock attracts high net worth investorsInsider Selling & Weekly Breakout Watchlists - Bộ Nội Vụ
PharmaCyte Biotech stock surges following profitable exit from Femasys investment - MSN
Hedge Fund and Insider Trading News: Paul Singer, Steve Cohen, Israel Englander, Ray Dalio, Rokos Capital Management, Viking Global, PharmaCyte Biotech Inc (PMCB), Cloudflare Inc (NET), and More - Insider Monkey
Why PharmaCyte Biotech Inc. stock could see breakout soonJuly 2025 Retail & Daily Growth Stock Tips - Улправда
Why PharmaCyte Biotech Inc. stock appeals to analystsJuly 2025 Outlook & Technical Entry and Exit Tips - Улправда
Will PharmaCyte Biotech Inc. stock rally after Fed decisionsWeekly Stock Report & Low Drawdown Trading Strategies - ulpravda.ru
How currency fluctuations impact PharmaCyte Biotech Inc. stockEarnings Summary Report & Long-Term Safe Investment Ideas - ulpravda.ru
Will PharmaCyte Biotech Inc. stock keep outperforming rivals2025 Sector Review & Risk Controlled Stock Alerts - Улправда
Jonathan Schechter buys PharmaCyte Biotech shares worth $48,232 By Investing.com - Investing.com Nigeria
Pharmacyte Biotech CEO Silverman buys $80k in shares By Investing.com - Investing.com Nigeria
PMCB Stock Insider Trading Activity - Quiver Quantitative
Jonathan Schechter buys PharmaCyte Biotech shares worth $48,232 - Investing.com
Pharmacyte Biotech CEO Silverman buys $80k in shares - Investing.com
How institutional buying supports PharmaCyte Biotech Inc. stockEarnings Per Share Trends & Minimal Investment Trading Tips - ulpravda.ru
PharmaCyte Biotech (PMCB) Stock Analysis Report | Financials & Insights - Benzinga
Largest borrow rate increases among liquid names - TipRanks
Will PharmaCyte Biotech Inc. stock benefit from infrastructure spending2025 Top Gainers & Weekly Breakout Watchlists - Улправда
Is PharmaCyte Biotech Inc. stock positioned for digital transformation2025 Trading Recap & Free Community Supported Trade Ideas - Улправда
How PharmaCyte Biotech Inc. stock reacts to job market dataJuly 2025 Pullbacks & Reliable Entry Point Trade Alerts - Улправда
How sustainable is PharmaCyte Biotech Inc. stock dividend payoutVolume Spike & Weekly Momentum Stock Picks - Улправда
Why PharmaCyte Biotech Inc. stock is a value investor pickShare Buyback & Expert Verified Stock Movement Alerts - Улправда
PharmaCyte Biotech, Inc. SEC 10-Q Report - TradingView — Track All Markets
Movement Recap: How sustainable is PharmaCyte Biotech Inc. stock dividend payoutJuly 2025 Chart Watch & Real-Time Stock Price Movement Reports - Улправда
PharmaCyte Biotech delays quarterly report filing - MSN
PharmaCyte Biotech Delays Quarterly Report Filing - TipRanks
PharmaCyte Biotech (PMCB) files notice of late Form 10-Q under Rule 12b-25 - Stock Titan
Dir Walker Surrenders 16,875 Of PharmaCyte Biotech Inc [PMCB] - TradingView — Track All Markets
PharmaCyte Biotech (PMCB) CEO nets 316,250 shares after tax withholding - Stock Titan
PharmaCyte Biotech faces NASDAQ non-compliance notice - MSN
Healthy Upside Potential: PharmaCyte Biotech Inc (PMCB) - setenews.com
PharmaCyte Biotech successfully monetizes Femasys stake - The Pharma Letter
PharmaCyte’s Successful Stake Earns them Millions - StocksToTrade
Pharmacyte Biotech Inc Stock (PMCB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):